# GLP-1 Alternatives: Next-Gen Weight-Loss Peptides Ranked by Evidence

> Beyond Ozempic and Wegovy: a clinical-evidence ranking of the next-generation metabolic peptides — the dual and triple incretin agonists and amylin analogues — for weight loss in 2026.

*Published 2026-06-30 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
Beyond single GLP-1 agonists like Ozempic and Wegovy, the next-generation metabolic peptides — the dual and triple incretin agonists and the amylin analogues — are the **one corner of peptide science where the human evidence is genuinely strong**. Every agent ranked here is backed by completed human randomized controlled trials — most by Phase 3 — and grades to **evidence level A** for weight loss. The honest catch is regulatory: with the sole exception of mazdutide (approved in China only), all of them remain **investigational and unavailable through any legal channel** in the US.[1](https://peptidevox.com/#r1)[20](https://peptidevox.com/#r20)

This page answers a specific question: beyond Ozempic/Wegovy-style single GLP-1 agonists, what is the evidence for the next-generation metabolic peptides as alternatives for weight loss? Unlike most of the peptide field — where 'fat-loss peptide' claims rest on animal models or anecdote — these agents are RCT-proven drugs, not grey-market speculation.[7](https://peptidevox.com/#r7)

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Doses are reported strictly as seen in the published trials, for completeness — never as recommendations. Decisions about obesity, diabetes, or metabolic disease belong with a qualified, licensed clinician.*

## Why call them GLP-1 'alternatives' at all?

'Alternative to GLP-1' is partly a misnomer. Most of these agents *contain or build on* GLP-1 agonism and add a second or third mechanism — the glucagon receptor, the GIP receptor, or the amylin receptor — on top of it. They are better understood as **GLP-1-plus** therapies than as GLP-1 replacements. Body-weight regulation is governed by energy intake (appetite, satiety, gastric emptying) and energy expenditure, integrated by gut–brain hormone signaling; the native incretin and satiety hormones — GLP-1, GIP, glucagon, oxyntomodulin, and amylin — are the levers these peptides pull. The next-gen strategy is combinatorial pharmacology: stack two or three of these mechanisms in one weekly injection to exceed the roughly 15–21% ceiling of single-mechanism drugs.[1](https://peptidevox.com/#r1)

The current approved benchmarks they are measured against are **semaglutide** (~15% mean weight loss at 68 weeks, STEP-1) and **tirzepatide** (~20.9% at 72 weeks, SURMOUNT-1; ~20.2% vs semaglutide's 13.7% head-to-head in SURMOUNT-5).[23](https://peptidevox.com/#r23)[24](https://peptidevox.com/#r24) The glucagon arm adds energy expenditure and hepatic fat oxidation; the GIP arm improves both glycemia and weight; and the amylin arm suppresses appetite through a hindbrain (area postrema) circuit largely non-overlapping with GLP-1's — which is why cagrilintide *adds* to semaglutide rather than duplicating it.[19](https://peptidevox.com/#r19)

## How do the next-gen peptides rank by evidence?

The ranking below weighs evidence strength and maturity, magnitude of weight loss, mechanistic rationale, and regulatory reality. The headline is rare for this field: this is real, RCT-proven science. The triple agonist **retatrutide** has produced the largest pharmacologic weight loss ever recorded — approaching bariatric-surgery territory — and **CagriSema** is the first to prove that amylin co-agonism adds to GLP-1 in humans.[2](https://peptidevox.com/#r2)[7](https://peptidevox.com/#r7)

  Next-gen GLP-1 alternatives, ranked by weight-loss evidence (2026)

    RankPeptideMechanismBest weight-loss dataApproval (2026)Grade

    1RetatrutideGIP + GLP-1 + glucagon triple agonist~24% (Ph2, 48 wk); up to ~28–30% (Ph3 TRIUMPH-1)InvestigationalA
    2CagriSemaAmylin + GLP-1~22.7% (Ph3 REDEFINE 1, 68 wk)NDA filed Dec 2025A
    3MazdutideGLP-1 + glucagon~12–15% (4–6 mg); ~20% (9 mg, 60 wk)Approved in ChinaA
    4SurvodutideGLP-1 + glucagon~16.6% (Ph3 SYNCHRONIZE-1, 76 wk)InvestigationalA
    5CagrilintideAmylin/calcitonin agonist~10.8% (Ph2); ~11.8% (Ph3 component)InvestigationalA (modest alone)

**Retatrutide** leads on magnitude: Phase 2 (NEJM 2023) reached −24.2% at 12 mg over 48 weeks without plateauing, and Phase 3 TRIUMPH-1 reported up to 28.3% at 80 weeks, with high-BMI participants reaching ~30.3% by 104 weeks.[1](https://peptidevox.com/#r1)[3](https://peptidevox.com/#r3) **CagriSema** brings the deepest dataset — REDEFINE 1 (n=3,417) showed −22.7% with clear additivity over either component, though it undershot guidance and lost the head-to-head to tirzepatide in REDEFINE 4.[7](https://peptidevox.com/#r7)[9](https://peptidevox.com/#r9) **Mazdutide** is the most regulatorily mature — actually approved in China — with ~20% at 9 mg, but its data are dominated by younger, lower-BMI Chinese cohorts.[12](https://peptidevox.com/#r12)[14](https://peptidevox.com/#r14) **Survodutide** trails on weight (~16.6%) but stands out for its MASH/liver program.[16](https://peptidevox.com/#r16)[17](https://peptidevox.com/#r17) **Cagrilintide** is modest alone (~10.8–11.8%); its value is as the amylin partner that makes CagriSema additive.[18](https://peptidevox.com/#r18)

Proven vs available
Proven: every agent here clears the human-RCT bar that the rest of the peptide field cannot. Available: only mazdutide, and only in China. The legitimate evidence is for the manufactured, clinically supervised drug inside a trial or an approved market — **not** for the lyophilized 'research peptide' sold online, which carries none of that safety net.[20](https://peptidevox.com/#r20)[21](https://peptidevox.com/#r21)

## What does the evidence NOT support?

Several common claims fail on the data. First, **'these are legal alternatives you can buy now'** is false for four of the five — retatrutide, survodutide, cagrilintide, and CagriSema are investigational and not approved in the US or EU, and none can be lawfully compounded.[20](https://peptidevox.com/#r20) Second, **'research-chemical peptide equals the trial drug'** is wrong: vials sold 'for research use only' are unapproved, unverified for identity, purity, and sterility, and the RCT efficacy and safety data do not transfer to them. You can confirm an agent's current trial and approval status directly via [ClinicalTrials.gov](https://clinicaltrials.gov/) before trusting any vendor claim. Third, **'newer is automatically better than tirzepatide'** is not established — CagriSema failed non-inferiority to tirzepatide head-to-head, and only retatrutide has clearly exceeded it on weight.[9](https://peptidevox.com/#r9) Fourth, **'you keep the weight off after stopping'** is not supported — weight regain after discontinuation is the documented pattern for the class. Fifth, **'it's pure fat loss'** is overstated: CagriSema substudies showed roughly 14% of weight lost was lean soft tissue, making protein intake and resistance training important adjuncts.[7](https://peptidevox.com/#r7)

## What are the safety, regulatory, and access realities in 2026?

The shared class safety profile is consistent. Gastrointestinal adverse events dominate — nausea, vomiting, diarrhea, constipation, decreased appetite — dose-related and concentrated during titration, with slower escalation reducing discontinuations.[15](https://peptidevox.com/#r15) A modest heart-rate increase appears across the incretin class, and lean-mass loss accompanies fat loss.[12](https://peptidevox.com/#r12) The glucagon-arm agents (retatrutide, survodutide, mazdutide) additionally raise ketones and warrant glucose and hepatic monitoring, though net glycemic control improved in the trials.[5](https://peptidevox.com/#r5) Theoretical, label-extrapolated contraindications include personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis, and gallbladder disease; pregnancy and breastfeeding are clear contraindications.[20](https://peptidevox.com/#r20)

On regulation: as of mid-2026, retatrutide, survodutide, cagrilintide, and CagriSema are **not FDA-approved** (CagriSema's NDA was filed December 2025, with a decision expected ~late 2026); mazdutide is approved only in China; and the newly approved oral orforglipron is a small molecule, not a peptide.[10](https://peptidevox.com/#r10)[25](https://peptidevox.com/#r25) None of the investigational peptides is eligible for 503A/503B compounding.[21](https://peptidevox.com/#r21) In sport, retatrutide is prohibited at all times under WADA (S0 + S2.4); the other unapproved agents fall under S0; 'research-chemical' labeling confers no anti-doping protection.[22](https://peptidevox.com/#r22) On cost, even the approved benchmarks are expensive — Wegovy lists ~$1,350–1,640/month and Zepbound ~$1,271/month — while the investigational next-gen peptides have no legal retail price at all.[26](https://peptidevox.com/#r26)

**Bottom line.** These peptides are real, RCT-proven drugs, and the science is the strongest in the entire peptide field. But for most people in 2026, the genuine, legal alternatives to a single GLP-1 are **tirzepatide, orforglipron, or a clinical trial** — not a peptide ordered online. Regulatory status in this field changes rapidly; verify current FDA/EMA/NMPA/WADA status before relying on any legal statement here.

---
Source: https://peptidevox.com/weight-and-metabolic/peptides-as-glp1-alternatives
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt